Kevin D. Burris - Concepedia

Author

Kevin D. Burris

Also Known As

Burris, K.D., Burris, Kevin D., K D Burris, K. Burris, K.D. Burris, KEVIN D. BURRIS, Kevin Burris, Kevin D Burris, Kevin D. Burris

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Otsuka (Japan)Vanderbilt University Eli Lilly (United States)Palatin Technologies (United States)

About

Kevin D. Burris is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	19	886
2	Biochemistry	8	8	260
3	Social Sciences	7	7	461
4	Natural Sciences	5	5	136
5	Behavioral Sciences	1	1	30

Kevin D. Burris

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors Kevin D. Burris, Thaddeus F. Molski, Cen Xu, Journal of Pharmacology and Experimental Therapeutics	2002	914
Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. Elaine Sanders‐Bush, Kevin D. Burris, Karen M. Knoth Journal of Pharmacology and Experimental Therapeutics	1988	155
Expression of the Human 5-Hydroxytryptamine1A Receptor in Sf9 Cells Paul Butkerait, Yejia Zheng, Hazem Hallak, Journal of Biological Chemistry	1995	154
Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies Arlene Stark, Shaun Jordan, Kelly A. Allers, Psychopharmacology Vivo Electrophysiological StudiesNeuropsychologyPsychoactive DrugPsychiatryNeurophysiology	2006	143
Mechanism of Action of Aripiprazole Predicts Clinical Efficacy and a Favourable Side-Effect Profile Tsuyoshi Hirose, Yasufumi Uwahodo, Sakiko Yamada, Journal of Psychopharmacology	2004	131
Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism Akihiko Kato, Kevin D. Burris, Kevin M. Gardinier, Nature Medicine Synaptic TransmissionNeurotransmitterNeuromodulation TherapiesSynaptic SignalingSocial Sciences	2016	88
Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic Yoshihiro Tadori, Takashi Miwa, Katsura Tottori, European Journal of Pharmacology Psychoactive DrugPsychiatryAddictionD2s ReceptorsMedicine	2005	85
Peroxidation of brain lipids following cyanide intoxication in mice Jerry D. Johnson, William G. Conroy, Kevin D. Burris, Toxicology MedicineLipid PeroxidationForensic ToxicologyToxicologyNeuroprotection	1987	82
The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release Koutoku Aihara, Jun Shimada, Takashi Miwa, Brain Research PsychiatryNovel Antipsychotic AripiprazolePharmacologyPsychopharmacologyPharmacological Agent	2004	62
(+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist. Kevin D. Burris, Marsha Breeding, Elaine Sanders‐Bush Journal of Pharmacology and Experimental Therapeutics	1991	62

Page 1